Usana Health Sciences (USNA) EBITDA (2010 - 2026)

Usana Health Sciences (USNA) has 17 years of EBITDA data on file, last reported at $13.9 million in Q2 2026.

• On a quarterly basis, EBITDA fell 11.47% year-over-year to $13.9 million in Q2 2026; TTM through Apr 2026 was $35.6 million, a 37.83% decrease from a year earlier, with the FY2026 full-year figure at $37.4 million, down 43.56% from the prior year.
• EBITDA for Q2 2026 stood at $13.9 million, up from $3.8 million in the prior quarter.
• Over the last five years, EBITDA for USNA reached as high as $46.2 million in Q1 2022 and fell as low as $1.2 million in Q3 2025.
• Historically, EBITDA has averaged $20.3 million across 5 years, with a median of $20.2 million in 2022.
• Across the five-year window, EBITDA climbed 7.4% in 2023 and slumped 92.15% in 2025, its largest moves.
• Year by year, EBITDA stood at $22.6 million in 2022, then increased by 7.4% to $24.2 million in 2023, then slumped by 66.1% to $8.2 million in 2024, then tumbled by 85.09% to $1.2 million in 2025, then soared by 1033.5% to $13.9 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $13.9 million in Q2 2026, $3.8 million in Q1 2026, and $1.2 million in Q3 2025.